Table 2.

Demographic and clinical characteristics of NSCLC COVID 19 patients.

Patient number	1	2	3	4	5	6
Sex	Man	Man	Woman	Woman	Man	Woman
Age, years	41	48	59	47	69	62
Smoking status	Current	Former	Never	Former	Former	Never
ECOG PS	1	1	1	0	1	1
Geographical area (region)	Lombardia	Lombardia	Emilia Romagna	Lombardia	Lazio	Lombardia
Co-morbidities	No	No	No	No	Yes	Yes
Histology	Non-squamous	Squamous	Non-squamous	Non-squamous	Non-squamous	Non-squamous
Stage	IV	IV	IV	IV	IV	IV
Clinical Trial	Yes	No	Yes	No	No	No
Treatment regimen	CHT-IO	IO	TKI	IO	IO	CHT
Line arms	1L	1L	2L	1L	2L	1L
No. of doses received	5	93	8	7	38	3
Phone call triage	Yes	Yes	Yes	Yes	Yes	Yes
Dilatation of anticancer treatments	No	Yes	No	Yes	Yes	No
Time between onset COVID 19 diagnosis and last clinical evaluation	11 days	1 day	10 days	26 days	37 days	21 days
Clinical Symptoms	Fever; cought; headache	None	None	Fever; cought; conjunctivitis; dysgeusia	Fever; myalgia	Rhinorrhea; cought
Concomitant treatment	Steroid	Steroid	Steroid	Steroid	Sartan	Steroid
Prior surgery	Yes	Yes	No	Yes	No	Yes
Prior RT	No	Yes	Yes	Yes	Yes	Yes
Contact with confirmed COVID 19 patient	Not certain	Not certain	Not certain	Not certain	Yes	Yes
CT diagnosis	Positive	Positive	Negative	Positive	Positive	Positive
SAR-COV 2 RT-PCR assay	Positive	Positive	Positive	Positive	Positive	Positive
Hospitalization status	Discharged	Not hospitalized	Not hospitalized	Not hospitalized	Inpatient	Not hospitalized
COVID 19 management	Darunavir/ritonavir/Hydroxychloroquine	Self-isolation at home	Hydroxychloroquine	Hydroxychloroquine	CPAP	Self-isolation at home
Survival status	Alive	Alive	Alive	Alive	Alive	Alive

NSCLC, non-small cell lung cancer; PS, perfprmance status; IO, immunotherapy; CHT, chemotherapy; RT, radiotherapy; TKI, tyrosine kinase inhibitor; CT, computed tomography; RT-PCR, real-time quantitative polymerase chain reaction; SARS-COV-2, severe acute respiratory syndrome coronavirus 2; CPAP, continuous positive airway pressure.